On this page
Folic Acid
Overview
Active ingredients
Source: NDC Directory| Ingredient | Strength | RxCUI | Monograph |
|---|---|---|---|
| Folic Acid | 5 mg/mL | 1720258 | View |
Forms, strengths and routes
Source: NDC DirectoryRegulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 089202-001 | FOLIC ACID | INJECTABLE | FOLIC ACID | Prescription | AP | RS |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — bioequivalence demonstrated (parenteral aqueous solutions)
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Supplement | 20 | Labeling | Approved | August 11, 2006 | — |
| Supplement | 15 | Labeling | Approved | March 21, 2006 | — |
| Supplement | 10 | Manufacturing (CMC) | Approved | December 5, 2002 | — |
| Supplement | 8 | Manufacturing (CMC) | Approved | January 20, 1995 | — |
| Supplement | 7 | Manufacturing (CMC) | Approved | July 6, 1990 | — |
| Supplement | 6 | Manufacturing (CMC) | Approved | December 8, 1988 | — |
| Supplement | 5 | Manufacturing (CMC) | Approved | December 8, 1988 | — |
| Supplement | 4 | Manufacturing (CMC) | Approved | December 8, 1988 | — |
| Supplement | 3 | Manufacturing (CMC) | Approved | December 8, 1988 | — |
| Original application | 1 | Approved | February 18, 1986 | — |
Review documents
- 0 · Original application · April 9, 2007
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260121). This is the manufacturer's labelling text, not a summary and not advice.
Indications and Usage
openFDA Drug LabelingINDICATIONS AND USAGE: Folic Acid Injection, USP alone is effective in the treatment of megaloblastic anemias due to a deficiency of folic acid as may be seen in tropical or nontropical sprue, in anemias of nutritional origin, pregnancy, infancy or childhood.
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION Parenteral Administration : Intramuscular (IM), intravenous (IV) and subcutaneous (SC) routes may be used if the disease is exceptionally severe or if gastrointestinal absorption may be, or is known to be, impaired. Usual Therapeutic Dosage — In adults and children (regardless of age): up to 1 mg daily. Resistant cases may require larger doses. Maintenance Level : When clinical symptoms have subsided and the blood picture has become normal, a maintenance level should be used, i.e., 0.1 mg for infants and up to 0.3 mg for children under four years of age, 0.4 mg for adults and children four or more years of age, and 0.8 mg for pregnant and lactating women, per day, but never less than 0.1 mg per day. Patient should be kept under close supervision and adjustment of the maintenance level made if relapse appears imminent. In the presence of alcoholism, hemolytic anemia, anticonvulsant therapy or chronic infection, the maintenance level may need to be increased. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Warnings
openFDA Drug LabelingWARNINGS: WARNING: This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum. Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration. Folic acid alone is improper therapy in the treatment of pernicious anemia and other megaloblastic anemias where Vitamin B 12 is deficient. This product contains benzyl alcohol. Benzyl alcohol has been reported to be associated with a fatal “Gasping Syndrome” in premature infants.
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS Allergic sensitization has been reported following both oral and parenteral administration of folic acid. To report SUSPECTED ADVERSE REACTIONS, contact XGen Pharmaceuticals DJB, Inc. at 1-866- 390-4411 or FDA at 1-800-FDA-1088 or www.fda. gov/medwatch.
Description
openFDA Drug LabelingDESCRIPTION: Folic Acid Injection, USP is a sterile, nonpyrogenic solution of sodium folate (prepared by the addition of sodium hydroxide to folic acid) in Water for Injection intended for intramuscular (IM), intravenous (IV) or subcutaneous (SC) use. Folic Acid is a complex organic compound present in liver, yeast and other substances, which may be prepared synthetically. It is a yellow or yellowish orange, odorless crystalline powder. It is very slightly soluble in water, insoluble in alcohol, chloroform, ether; readily dissolves in dilute solutions of alkali hydroxides and carbonates. It is chemically designated as: L-Glutamic acid, N -[4-[[(2-amino-1-4-dihydro-4-oxo-6-pteridinyl) methyl] amino]benzoyl]-, and has the following structural formula. C 19 H 19 N 7 O 6 M.W. 441.40 Each mL contains: Sodium folate (equivalent to 5 mg folic acid); edetate disodium 2 mg; benzyl alcohol 15 mg (added as preservative); Water for Injection q.s. Hydrochloric acid and/or sodium hydroxide for pH adjustment (8.0 to 11.0). folic acid structure
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED Folic Acid Injection, USP 50 mg per 10 mL (5 mg per mL) is available as: Product NDC: 39822-1100-1 10 mL Multiple Dose, in a flip-top vial, packaged individually. Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. PROTECT FROM LIGHT. Retain vial in carton until contents are used. Manufactured in India. Manufactured by: Anthea Pharma Private Limited Mfg. Lic: TS/SGY/2023-112201 Manufactured for: XGen Pharmaceuticals DJB, Inc. Big Flats, NY 14814 Revised: August 2025 FOLI-AN-PI-00 1500105 logo Rx Only
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: FOLIC ACID. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 63323-184-10 | 63323-184 | Fresenius Kabi USA, LLC | 1 VIAL, MULTI-DOSE in 1 CARTON (63323-184-10) / 10 mL in 1 VIAL, MULTI-DOSE | September 5, 2000 |
| 39822-1100-1 | 39822-1100 | XGen Pharmaceuticals DJB, Inc. | 1 VIAL, MULTI-DOSE in 1 CARTON (39822-1100-1) / 10 mL in 1 VIAL, MULTI-DOSE | November 17, 2019 |
| 63323-184 | 63323-184 | Fresenius Kabi USA, LLC | — | September 5, 2000 |
| 39822-1100 | 39822-1100 | XGen Pharmaceuticals DJB, Inc. | — | November 17, 2019 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
Generated September 25, 2026 · 11 sections on this page.